Onco-Innovations Advances ONC010 Toward First-in-Human Trials
August 14, 2026 — Onco-Innovations advances ONC010, a nanoparticle PNKP inhibitor, with key manufacturing and metabolism studies, moving closer to first-in-human trials for biomarker-selected cancers.